Clinical proteomics: Translating benchside promise into bedside reality

Nature Reviews Drug Discovery

Volumn 1, Issue 9, 2002, Pages 683-695

  Petricoin, Emanuel F ^a   Zoon, Kathryn C ^a   Kohn, Elise C ^b   Barrett, J Carl ^b   Liotta, Lance A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; PROTEIN KINASE INHIBITOR; DIAGNOSTIC AGENT; PROTEOME;

BIOTECHNOLOGY; CANCER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG MECHANISM; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; INFORMATION PROCESSING; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS; REVIEW; TREATMENT PLANNING; BIOLOGICAL MODEL; CHEMISTRY; DNA MICROARRAY; FEMALE; METABOLISM; NEOPLASM; PHARMACEUTICS; PHYSIOLOGY;

FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036718796     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd891     Document Type: Review

References (83)

1. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48-56 (2000).
2. Ideker, T. et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929-934 (2001).
3. Schwikowski, B., Uetz, P. & Fields, S. A network of protein-protein interactions in yeast. Nature Biotechnol. 18, 1257-1261 (2000).
4. Legrain, P., Jestin, J. L. & Schachter, V. From the analysis of protein complexes to proteome-wide linkage maps. Curr. Opin. Biotechnol. 4, 402-407 (2000).
5. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signaling. Nature 411, 355-365 (2001).
6. Pawson, T. Protein modules and signaling networks. Nature 373, 573-580 (1995).
7. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
8. Ozols, R. F., Rubin, S. C., Thomas, G. M. & Robboy, S. J. in Principles and Practice of Gynecologic Oncology (eds Hoskins, W. J., Perez, C. A. & Young, R. C.) 981-1058 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2000).
9. Menon, U. & Jacobs, I. in Principles and Practice of Gynecologic Oncology (eds Hoskins, W. J., Perez, C. A. &, Young, R. C.) 165-182 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2000).
10. Bast, R. C. et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887 (1983).
11. Menon, U. & Jacobs, I. J. Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 12, 39-42 (2000).
12. Jacobs, I. J. et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353, 1207-1210 (1999).
13. Cohen, L. S., Escobar P. F, Scharm, C., Glimco, B. & Fishman, D. A. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol. Oncol. 82, 40-48 (2001).
14. Adam, B. L., Vlahou, A., Semmes, O. J. & Wright, G. L. Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1, 1264-1270 (2001).
15. Carter, D. et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41, 6714-6722 (2002).
16. Rosty, C. et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62, 1868-1875 (2002).
17. Xiao, Z. et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 6029-6033 (2001).
18. Kim, J. H. et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287, 1671-1679 (2002).
19. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
20. Ball, G. et al. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18, 395-404 (2002).
21. Ting, K. L., Lee, R. C., Chang, C. L. & Guarino, A. M. The relationship between the mass spectra of drugs and their biological activity - an application of artificial intelligence to chemistry. Comput. Biol. Med. 4, 301-332 (1975).
22. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153-161 (2002).
23. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
24. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
25. Lindahl, D., Palmer, J. & Edenbrandt, L. Myocardial SPET: artificial neural networks describe extent and severity of perfusion defects. Clin. Physiol. 19, 497-503 (1999).
26. Lapuerta, P. et al. Neural network assessment of perioperative cardiac risk in vascular surgery patients. Med. Decis. Making 18, 70-75 (1998).
27. Holland, J. H. (ed.) Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence 3rd edn (MIT Press, Cambridge, Massachusetts, 1994).
28. Kohonen, T. Self-organizing formation of topologically correct feature maps. Biol. Cybernetics 43, 59-69 (1982).
29. Kohonen, T. The self-organizing map. Proc. IEEE 78, 1464-1480 (1990).
30. Tou, J. T. & Gonzalez, R. (eds) in Pattern Recognition Principles (eds Tou, J. T. & Gonzalez, R.) 75-109 (Addison Weley, Reading, Massachusetts, 1974).
31. Stoeckli, M., Chaurand, P. Hallahan, D. E. & Caprioli, R. M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nature Med. 7, 493-496 (2001).
32. Emmert-Buck, M. R. et al. Laser capture microdissection. Science 274, 998-1001 (1996).
33. Emmert-Buck, M. R. et al. An approach to proteomic analysis of human tumors. Mol. Carcinog. 27, 158-165 (2000).
34. Craven, R. A., Totty, N., Harnden, P., Selby, P. J. & Banks, R. E. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am. J. Pathol. 160, 815-822 (2002).
35. Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235-2242 (2000).
36. Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205-1215 (2001).
37. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84 (2002).
38. Knezevic, V. et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1, 1271-1278 (2001).
39. Ahram, M. et al. Proteomic analysis of human prostate cancer. Mol. Carcinog. 33, 9-15 (2002).
40. Gorg, A. et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21, 1037-1053 (2000).
41. Hanash, S. M. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 21, 1202-1209 (2000).
42. Herbert, B. R., Sanchez, J.-C. & Bini, L. in Proteome Reseach: New Frontiers in Functional Genomics Ch. 2 (eds Wilkens, M. R., Williams, K. L., Appel, R. D. & Hochstrasser, D. F.) 13-30 (Springer-Verlag, New York, 1997).
43. Shen, Y. et al. High-throughput proteomics using high-efficiency multiple-capillary liquid chromatography with on-line high-performance ESI FTICR mass spectrometry. Anal. Chem. 73, 3011-3021 (2001).
44. Li, J., Wang, C., Kelly, J. F., Harrison, D. J. & Thibault, P. Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole-time-of-flight mass spectrometer. Electrophoresis 21, 198-210 (2000).
45. Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope coded affinity tags. Nature Biotechnol. 17, 994-999 (1999).
46. Washburn, M. P., Wolters, D. & Yates, J. R. Large scale analysis of the yeast proteome by multidimensional protein identification technology. Nature Biotechnol, 19, 242-247 (2001).
47. Krutchinsky, A. N., Kalkum, M. & Chait, B. T. Automatic identification of proteins with a MALDI-quadrupole ion trap mass spectrometer. Anal. Chem. 73, 5066-5077 (2001).
48. Washburn, M. P., Ulaszek, R., Deciu, C., Schieltz, D. M. & Yates, J. R. Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal. Chem. 74, 1650-1657 (2002).
49. Zhou, H., Ranish, J. A., Watts, J. D. & Aebersold, R. Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nature Biotechnol. 20, 512-515 (2002).
50. Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of human esophageal squamous cell cancer-specific protein markers Mol. Cell. Proteomics 1, 117-123 (2002).
51. Sreekumar, A. et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61, 7585-7593 (2001).
52. MacBeath, G. Proteomics comes to the surface. Nature Biotechnol. 19, 828-829 (2001).
53. Walter, G., Bussow, K., Lueking, A. & Glokler, J. High-throughput protein arrays: prospects for molecular diagnostics. Trends Mol. Med. 8, 250-253 (2002).
54. Kuruvilla, F. G., Shamji, A. F., Sternson, S. M., Hergenrother, P. J. & Schreiber, S. L. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416, 653-657 (2002).
55. Paweletz, C. P. et al. Reverse-phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
56. Torhorst, J. et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249-2256 (2001).
57. Vile, R. G., Russell, S. J. & Lemoine, N. R. Cancer gene therapy: hard lessons and new courses. Gene Ther. 7, 2-8 (2000).
58. Wiebe, L. I. & Knaus, E. E. Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression. Curr. Pharm. Des. 7, 1893-1906 (2001).
59. Liotta, L. A., Kohn, E. C. & Petricoin, E. F. Clinical proteomics: personalized molecular medicine. JAMA 286, 2211-2214 (2001).
60. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48-56 (2000).
61. Karpati, G., Li, H. & Nalbantoglu, J. Molecular therapy for glioblastoma. Curr. Opin. Mol. Ther. 1, 545-552 (1999).
62. Brown, C. K. & Kirkwood, J. M. Targeted therapy for malignant melanoma. Curr. Oncol. Rep. 3, 344-352 (2001).
63. Frankel, A. E., Sievers, E. L. & Scheinberg, D. A. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother. Radiopharm. 15, 459-476 (2000).
64. Cheng, J. D., Rieger, P. T., von Mehren, M., Adams, G. P. & Weiner, L. M. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin. Oncol. Nurs. 16 (Suppl. 1), 2-12 (2000).
65. Gasparini, G. & Gion, M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J. Sci. Am. 6, 117-131 (2000).
66. Cimoli, G. et al. Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori. 87, S20-S23 (2001).
67. Kolonin, M., Pasqualini, R. & Arap, W. Molecular addresses in blood vessels as targets for therapy. Curr. Opin. Chem. Biol. 5, 308-313 (2001).
68. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
69. Ponder, B. A. Cancer genetics. Nature 411, 337-341 (2001).
70. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001).
71. Kaptain, S., Tan, L. K. & Chen, B. HER2/NEU and breast cancer. Diagn. Mol. Pathol. 10, 139-152 (2001).
72. Leyland-Jones, B. Trastuzumab: hopes and realities. Lancet Oncol. 3, 137-144 (2002).
73. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599 (2000).
74. Santen, R. J. et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80, 239-256 (2002).
75. Thiesing, J. T, Ohno-Jones, S., Kolibaba, K. S. & Druker, B. J. Efficacy of STI571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells. Blood 96, 3195-3199 (2000).
76. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
77. Vlahos, C. J. & Stancato, L. F. in Platelets and Megakaryoctyes: Methods and Protocols (eds Gibbons, J. M. & Mahaut-Smith, M. P.) (Humana, Tolowa, New Jersey, 2002).
78. Traxler, P. et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499-512 (2001).
79. Zwick, E., Bange, J. & Ullrich, A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8, 17-23 (2002).
80. Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65-72 (2002).
81. Moasser M. M., Basso, A., Averbuch, S. D. & Rosen, N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184-7188 (2001).
82. Cuello, M. et al. Down-regulation of the ERBB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ERBB-2. Cancer Res. 15, 4892-4900 (2001).
83. Paweletz, C.-P. et al. Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev. Res. 49, 34-42 (2000).